517 related articles for article (PubMed ID: 15705083)
1. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
2. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
3. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
5. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
Kirby RS
BJU Int; 2003 Jan; 91(1):41-4. PubMed ID: 12614248
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
Kirby RS; O'Leary MP; Carson C
BJU Int; 2005 Jan; 95(1):103-9; discussion 109. PubMed ID: 15638905
[TBL] [Abstract][Full Text] [Related]
11. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
Kirby RS; Andersen M; Gratzke P; Dahlstrand C; Høye K
BJU Int; 2001 Feb; 87(3):192-200. PubMed ID: 11167641
[TBL] [Abstract][Full Text] [Related]
12. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
Andersen M; Dahlstrand C; Høye K
Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
[TBL] [Abstract][Full Text] [Related]
14. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
Hernandez C; Duran R; Jara J; Castaño I; Moralejo M
Prostate Cancer Prostatic Dis; 2005; 8(4):375-80. PubMed ID: 16264771
[TBL] [Abstract][Full Text] [Related]
15. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
16. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
Roehrborn CG; Prajsner A; Kirby R; Andersen M; Quinn S; Mallen S
Eur Urol; 2005 Sep; 48(3):445-52; discussion 452. PubMed ID: 15996811
[TBL] [Abstract][Full Text] [Related]
17. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
18. Clinical ease of using doxazosin in BPH patients with and without hypertension.
Steers WD; Kirby RS
Prostate Cancer Prostatic Dis; 2005; 8(2):152-7. PubMed ID: 15711605
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
20. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
Zhang K; Yu W; Jin J; Ye H; Wang X; Zhang N; Yang Y; Zhong C; Wan B
Urology; 2011 Sep; 78(3):636-40. PubMed ID: 21696807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]